Top

Published in:

01-04-2019 | Original Article

Protein Expression Analysis in Uterine Cervical Cancer for Potential Targets in Treatment

Authors: Sugela Blancas, Rogelio Medina-Berlanga, Liliana Ortíz-García, Alfredo Loredo-Ramírez, Leticia Santos

Published in: Pathology & Oncology Research | Issue 2/2019

Abstract

Specific markers in lesions of the human uterine cervix cancer (UCC) are still needed for prognostic, diagnostic and/or therapeutic purposes. In this study we evaluated key molecules at protein level between normal epithelium, cervical intraepithelial neoplasia (CIN1–3) and invasive cancer of a group of molecules previously reported at mRNA level. For that purpose, human formalin-fixed paraffin embedded tissue microarrays (TMAs) were constructed containing 205 Mexican tissue core specimens. Immunohistochemistry and quantitative analysis of histological staining was performed against twenty-two distinct proteins for each core and the processing platform ImageJ. In the progression of the disease we found key statistical differences for the proteins SEL1, Notch3 and SOCS3. High expressions of SEL1L, Notch3 and SOCS3 have potential value to increase the prognostic of UCC in combination with markers such as p16^INK4a. This study identified key drivers in cervical carcinogenesis that should be evaluated for the development of UCC therapies.

Available only for authorised users

Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189(1):12–19. https://doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F CrossRef

Malinowski DP (2007) Multiple biomarkers in molecular oncology. I. Molecular diagnostics applications in cervical cancer detection. Expert Rev Mol Diagn 7(2):117–131. https://doi.org/10.1586/14737159.7.2.117 CrossRefPubMed

Brown CA, Bogers J, Sahebali S, Depuydt CE, De Prins F, Malinowski DP (2012) Role of protein biomarkers in the detection of high-grade disease in cervical cancer screening programs. J Oncol 2012:289315–289311. https://doi.org/10.1155/2012/289315 CrossRefPubMedPubMedCentral

Santos L, Leon-Galvan MF, Marino-Marmolejo EN, Barba de la Rosa AP, De Leon RA, Gonzalez-Amaro R, Guevara-Gonzalez RG (2011) Identification of differential expressed transcripts in cervical cancer of Mexican patients. Tumour Biol: J Int Soc Oncodev Biol Med 32(3):561–568. https://doi.org/10.1007/s13277-010-0151-4 CrossRef

Palermo R, Checquolo S, Bellavia D, Talora C, Screpanti I (2014) The molecular basis of notch signaling regulation: a complex simplicity. Curr Mol Med 14(1):34–44CrossRefPubMed

Allenspach EJ, Maillard I, Aster JC, Pear WS (2002) Notch signaling in cancer. Cancer Biol Ther 1(5):466–476CrossRefPubMed

Arafa M, Boniver J, Delvenne P (2010) Progression model tissue microarray (TMA) for the study of uterine carcinomas. Dis Markers 28(5):267–272. https://doi.org/10.3233/DMA-2010-0709 CrossRefPubMedPubMedCentral

Zhu H, Zhou X, Redfield S, Lewin J, Miele L (2013) Elevated Jagged-1 and Notch-1 expression in high grade and metastatic prostate cancers. Am J Transl Res 5(3):368–378PubMedPubMedCentral

Cornish TC, Halushka MK (2009) Color deconvolution for the analysis of tissue microarrays. Anal Quant Cytol Histol/ Int Acad Cytol Am Soc Cytol 31(5):304–312

10.

Shapiro SS, Wilk MB (1965) An analysis of variance test for normality (complete samples). Biometrika 52:591-&. https://doi.org/10.2307/2333709

11.

Keyes TK, Levy MS (1997) Analysis of Levene's test under design imbalance. J Educ Behav Stat 22(2):227–236

12.

Box GEP, Cox DR (1964) An analysis of transformations. J Roy Stat Soc B 26(2):211–252

13.

Cicchett Dv, Collins D, Latvis V (1972) Program for Comparing Group Means - One-Way Anova and Tukey Multiple-Range Tests. Behav Sci 17 (4):399-&

14.

Keselman HJ, Murray R (1974) Tukey tests for pair-wise contrasts following analysis of variance - is there a type 4 error. Psychol Bull 81(9):608–609. https://doi.org/10.1037/h0036938 CrossRef

15.

Li JJ (2011) A simple and flexible holm gatekeeping procedure. Biom J 53(5):797–809. https://doi.org/10.1002/bimj.201000040 CrossRefPubMed

16.

Ikenberg H, Bergeron C, Schmidt D, Griesser H, Alameda F, Angeloni C, Bogers J, Dachez R, Denton K, Hariri J, Keller T, von Knebel Doeberitz M, Neumann HH, Puig-Tintore LM, Sideri M, Rehm S, Ridder R, Group PS (2013) Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study. J Natl Cancer Inst 105(20):1550–1557. https://doi.org/10.1093/jnci/djt235 CrossRefPubMedPubMedCentral

17.

Wentzensen N, Fetterman B, Castle PE, Schiffman M, Wood SN, Stiemerling E, Tokugawa D, Bodelon C, Poitras N, Lorey T, Kinney W (2015) p16/Ki-67 dual stain cytology for detection of cervical Precancer in HPV-positive women. J Natl Cancer Inst 107(12):djv257. https://doi.org/10.1093/jnci/djv257 CrossRefPubMedPubMedCentral

18.

Garner DM (2016) RE: p16/Ki-67 dual stain cytology for detection of cervical Precancer in HPV-positive women. J Natl Cancer Inst 108(2):djv389. https://doi.org/10.1093/jnci/djv389 CrossRefPubMed

19.

Benczik M, Galamb A, Koiss R, Kovacs A, Jaray B, Szekely T, Szekerczes T, Schaff Z, Sobel G, Jeney C (2016) Claudin-1 as a biomarker of cervical cytology and histology. Pathol Oncol Res 22(1):179–188. https://doi.org/10.1007/s12253-015-9990-z CrossRefPubMed

20.

Klaes R, Friedrich T, Spitkovsky D, Ridder R, Rudy W, Petry U, Dallenbach-Hellweg G, Schmidt D, von Knebel Doeberitz M (2001) Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 92(2):276–284CrossRefPubMed

21.

Volgareva G, Zavalishina L, Andreeva Y, Frank G, Krutikova E, Golovina D, Bliev A, Spitkovsky D, Ermilova V, Kisseljov F (2004) Protein p16 as a marker of dysplastic and neoplastic alterations in cervical epithelial cells. BMC Cancer 4(58). https://doi.org/10.1186/1471-2407-4-58

22.

Harada Y, Ozaki K, Suzuki M, Fujiwara T, Takahashi E, Nakamura Y, Tanigami A (1999) Complete cDNA sequence and genomic organization of a human pancreas-specific gene homologous to Caenorhabditis elegans sel-1. J Hum Genet 44(5):330–336. https://doi.org/10.1007/s100380050171 CrossRefPubMed

23.

Li S, Francisco AB, Munroe RJ, Schimenti JC, Long Q (2010) SEL1L deficiency impairs growth and differentiation of pancreatic epithelial cells. BMC Dev Biol 10:19. https://doi.org/10.1186/1471-213X-10-19 CrossRefPubMedPubMedCentral

24.

Cattaneo M, Lotti LV, Martino S, Alessio M, Conti A, Bachi A, Mariani-Costantini R, Biunno I (2011) Secretion of novel SEL1L endogenous variants is promoted by ER stress/UPR via endosomes and shed vesicles in human cancer cells. PLoS One 6(2):e17206. https://doi.org/10.1371/journal.pone.0017206 CrossRefPubMedPubMedCentral

25.

Ashktorab H, Green W, Finzi G, Sessa F, Nouraie M, Lee EL, Morgano A, Moschetta A, Cattaneo M, Mariani-Costantini R, Brim H, Biunno I (2012) SEL1L, an UPR response protein, a potential marker of colonic cell transformation. Dig Dis Sci 57(4):905–912. https://doi.org/10.1007/s10620-011-2026-y CrossRefPubMedPubMedCentral

26.

Wang SS, Hsiao R, Limpar MM, Lomahan S, Tran TA, Maloney NJ, Ikegaki N, Tang XX (2014) Destabilization of MYC/MYCN by the mitochondrial inhibitors, metaiodobenzylguanidine, metformin and phenformin. Int J Mol Med 33(1):35–42. https://doi.org/10.3892/ijmm.2013.1545 CrossRefPubMed

27.

Duffy DJ, Krstic A, Schwarzl T, Higgins DG, Kolch W (2014) GSK3 inhibitors regulate MYCN mRNA levels and reduce neuroblastoma cell viability through multiple mechanisms, including p53 and Wnt signaling. Mol Cancer Ther 13(2):454–467. https://doi.org/10.1158/1535-7163.MCT-13-0560-T CrossRefPubMed

28.

Kang JH, Rychahou PG, Ishola TA, Qiao J, Evers BM, Chung DH (2006) MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells. Biochem Biophys Res Commun 351(1):192–197. https://doi.org/10.1016/j.bbrc.2006.10.020 CrossRefPubMedPubMedCentral

29.

Cui H, Kong Y, Xu M, Zhang H (2013) Notch3 functions as a tumor suppressor by controlling cellular senescence. Cancer Res 73(11):3451–3459. https://doi.org/10.1158/0008-5472.CAN-12-3902 CrossRefPubMedPubMedCentral

30.

Jaskula-Sztul R, Eide J, Tesfazghi S, Dammalapati A, Harrison AD, Yu XM, Scheinebeck C, Winston-McPherson G, Kupcho KR, Robers MB, Hundal AK, Tang W, Chen H (2015) Tumor-suppressor role of Notch3 in medullary thyroid carcinoma revealed by genetic and pharmacological induction. Mol Cancer Ther 14(2):499–512. https://doi.org/10.1158/1535-7163.MCT-14-0073 CrossRefPubMed

31.

Pelullo M, Quaranta R, Talora C, Checquolo S, Cialfi S, Felli MP, te Kronnie G, Borga C, Besharat ZM, Palermo R, Di Marcotullio L, Capobianco AJ, Gulino A, Screpanti I, Bellavia D (2014) Notch3/Jagged1 circuitry reinforces notch signaling and sustains T-ALL. Neoplasia 16(12):1007–1017. https://doi.org/10.1016/j.neo.2014.10.004 CrossRefPubMedPubMedCentral

32.

Jung JG, Stoeck A, Guan B, Wu RC, Zhu H, Blackshaw S, Shih Ie M, Wang TL (2014) Notch3 interactome analysis identified WWP2 as a negative regulator of Notch3 signaling in ovarian cancer. PLoS Genet 10(10):e1004751. https://doi.org/10.1371/journal.pgen.1004751 CrossRefPubMedPubMedCentral

33.

Bianchi L, Canton C, Bini L, Orlandi R, Menard S, Armini A, Cattaneo M, Pallini V, Bernardi LR, Biunno I (2005) Protein profile changes in the human breast cancer cell line MCF-7 in response to SEL1L gene induction. Proteomics 5(9):2433–2442. https://doi.org/10.1002/pmic.200401283 CrossRefPubMed

34.

Yeasmin S, Nakayama K, Rahman MT, Rahman M, Ishikawa M, Iida K, Otsuki Y, Kobayashi H, Nakayama S, Miyazaki K (2010) Expression of nuclear Notch3 in cervical squamous cell carcinomas and its association with adverse clinical outcomes. Gynecol Oncol 117(3):409–416. https://doi.org/10.1016/j.ygyno.2010.03.004 CrossRefPubMed

35.

Tripathi R, Rath G, Jawanjal P, Sharma S, Singhal P, Bhambhani S, Hussain S, Bharadwaj M (2014) Clinical impact of de-regulated Notch-1 and Notch-3 in the development and progression of HPV-associated different histological subtypes of precancerous and cancerous lesions of human uterine cervix. PLoS One 9(6):e98642. https://doi.org/10.1371/journal.pone.0098642 CrossRefPubMedPubMedCentral

36.

Bellavia D, Campese AF, Alesse E, Vacca A, Felli MP, Balestri A, Stoppacciaro A, Tiveron C, Tatangelo L, Giovarelli M, Gaetano C, Ruco L, Hoffman ES, Hayday AC, Lendahl U, Frati L, Gulino A, Screpanti I (2000) Constitutive activation of NF-kappaB and T-cell leukemia/lymphoma in Notch3 transgenic mice. EMBO J 19(13):3337–3348. https://doi.org/10.1093/emboj/19.13.3337 CrossRefPubMedPubMedCentral

37.

Bellavia D, Campese AF, Checquolo S, Balestri A, Biondi A, Cazzaniga G, Lendahl U, Fehling HJ, Hayday AC, Frati L, von Boehmer H, Gulino A, Screpanti I (2002) Combined expression of pTalpha and Notch3 in T cell leukemia identifies the requirement of preTCR for leukemogenesis. Proc Natl Acad Sci U S A 99 (6):3788–3793. https://doi.org/10.1073/pnas.062050599

38.

Zhang Y, Jia L, Lee SJ, Wang MM (2007) Conserved signal peptide of Notch3 inhibits interaction with proteasome. Biochem Biophys Res Commun 355(1):245–251. https://doi.org/10.1016/j.bbrc.2007.01.151 CrossRefPubMedPubMedCentral

39.

Palermo R, Checquolo S, Giovenco A, Grazioli P, Kumar V, Campese AF, Giorgi A, Napolitano M, Canettieri G, Ferrara G, Schinina ME, Maroder M, Frati L, Gulino A, Vacca A, Screpanti I (2012) Acetylation controls Notch3 stability and function in T-cell leukemia. Oncogene 31(33):3807–3817. https://doi.org/10.1038/onc.2011.533 CrossRefPubMed

40.

Sasi W, Sharma AK, Mokbel K (2014) The role of suppressors of cytokine signalling in human neoplasms. Mol Biol Int 2014(630797):1–24. https://doi.org/10.1155/2014/630797 CrossRef

41.

Puhr M, Santer FR, Neuwirt H, Marcias G, Hobisch A, Culig Z (2010) SOCS-3 antagonises the proliferative and migratory effects of fibroblast growth factor-2 in prostate cancer by inhibition of p44/p42 MAPK signalling. Endocr Relat Cancer 17(2):525–538. https://doi.org/10.1677/ERC-10-0007 CrossRefPubMed

42.

Kim MH, Kim MS, Kim W, Kang MA, Cacalano NA, Kang SB, Shin YJ, Jeong JH (2015) Suppressor of cytokine signaling (SOCS) genes are silenced by DNA hypermethylation and histone deacetylation and regulate response to radiotherapy in cervical cancer cells. PLoS One 10(4):e0123133. https://doi.org/10.1371/journal.pone.0123133 CrossRefPubMedPubMedCentral

Title: Protein Expression Analysis in Uterine Cervical Cancer for Potential Targets in Treatment
Authors: Sugela Blancas
Rogelio Medina-Berlanga
Liliana Ortíz-García
Alfredo Loredo-Ramírez
Leticia Santos
Publication date: 01-04-2019
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 2/2019
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-018-0401-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2019

JAK Pseudokinase Domain Variants Highlight nRTK VUSs Identified with Next-Generation Sequencing in Solid Tumor Patients

Identification of Long Noncoding RNA MIR22HG as a Novel Biomarker in Thyroid Cancer

Saliva as a Diagnostic Tool in Oral Squamous Cell Carcinoma – a Systematic Review with Meta Analysis

Unsupervised Clustering of Immunohistochemical Markers to Define High-Risk Endometrial Cancer

Gene Promoter Methylation in Endometrial Carcinogenesis

Prognostic and Clinic-Pathological Significances of SCF and COX-2 Expression in Inflammatory and Malignant Prostatic Lesions

Keynote webinar | Spotlight on antibody–drug conjugates in cancer